Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma

Journal of Nuclear Medicine

Volumn 39, Issue 12, 1998, Pages 2090-2094

  Leimer, Maria ^b   Kurtaran, Amir ^b   Smith Jones, Peter ^b   Raderer, Markus ^b   Havlik, Ernst ^b   Angelberger, Peter ^b   Vorbeck, Friedrich ^b   Niederle, Bruno ^b   Herold, Christian ^b   Virgolini, Irene ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

DOTA lanreotide; Gastrinoma; Somatostatin receptor; Tumor radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACETIC ACID DERIVATIVE; ANGIOPEPTIN; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL TUMOR; ADULT; ARTICLE; CASE REPORT; GASTRINOMA; HUMAN; LIVER METASTASIS; MALE; PRIORITY JOURNAL; RADIATION DOSE; TUMOR SCINTISCANNING;

GASTRINOMA; HETEROCYCLIC COMPOUNDS; HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RECURRENCE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032407290     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-1249.
2. 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med 1996;23:1388-1399.
3. 111In-DTPA-D-Phel-octreotide. Ann N Y Acad Sci 1994;733:496-506.
4. Smith-Jones P, Bischof C, Leimer M, et al. "MAURITIUS" a novel somatostatin analog for tumor diagnosis and therapy [Abstract]. J Nucl Med 1998;39:223P.
5. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 1997;27:645-647.
6. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928-1936.
7. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(suppl):57-61.
8. Anderson CJ, Pajeaun TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64 octreotide conjugates. J Nucl Med 1995;36:2315-2325.
9. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Reston, VA: Society of Nuclear Medicine; 1988.
10. Herpst JM, Klein JL, Leichner PK, Quadri SM, Vriesendorp HM. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 1995;13:2394-2400.
11. Hiruma K, Koike T, Nakamura H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 1990;71:480-485.
12. Modlin IM, Tang LH. The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology 1996;111:783- 810.
13. Kvols LK. Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of rumors. Gastroenterology 1993;105:1909-1914.
14. Eriksson B, Janson ET, Bax ND, et al. The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastrointestinal tumours. Digestion 1996;1(suppl): 77-80.
15. Beales IL, Post L, Calam J, Yamada T, Delvalle J. Tumour necrosis factor alpha stimulates gastrin release from canine and human antral G cells: possible mechanism of the Helicobacter pylori-gastrin link. Eur J Clin Invest 1996;26:609-611.
16. Shiratori K, Watanabe S, Takeuchi T. Intestinal fat digestion plays a significant role in fat-induced suppression of gastric acid secretion and gastrin release in the rat. Dig Dis Sci 1993;38:2267-2672.
17. Modlin IM, Lewis JJ, Ahlman II, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surgery 1993;176:507-518.